Table 2.

Effect of Gefitinib or/and CDDP on the amount of peripheral blood cells of mice bearing H22 tumors (mean±SD).

Groups	n		WBC (109/L)		RBC (109/L)		HB (g/L)		PLT(109/L)
	Exp 1	Exp 2	Exp 1	Exp 2	Exp 1	Exp 2	Exp 1	Exp 2	Exp 1	Exp 2
Lecithin control	14	14	7.6±1.8	8.5±1.8	6.8±2.3	7.5±1.1	110.2±14.8	126.6±16.5	1259.1±336.4	1051.4±208.7
NS control	13	14	7.6±1.7	8.4±1.7	6.5±3.2	8.0±1.8	108.4±14.0	125.2±13.5	1149.2±304.4	1057.1±200.4
CDDP d1-5	14	13	6.6±1.8	6.7±2.3a	5.5±3.5a	6.7±0.9a	120.4±16.6	124.5±9.6	542.9±256.4b	589.2±190.3b
CDDP d6-10	12	14	7.7±1.4	6.8±1.9	5.9±2.8	6.7±1.1	117.2±9.8	122.6±18.6	1318.7±829.8	1100.1±281.9
Gefitinib d1-10	14		8.2±2.8		6.2±3.8		116.3±15.6		1203.3±310.5
Gefitinib d1-5		14		9.9±2.5		7.7±1.2		127.9±15.2		1100.3±170.6
Gefitinib d1-10	13		7.2±2.9		6.4±2.3		124.0±16.7		523.8±252.9b
+CDDP d1-5
Gefitinib d1-10	14		7.7±2.5		6.8±1.2		123.9±8.3		1307.5±474.4
+CDDP d6-10
Gefitinib d1-5		14		8.2±2.4		6.9±1.3		122.9±18.6		589.9±168.4b
+CDDP d1-5
CDDPd1-5		13		7.8±1.7		7.3±1.1		126.1±19.3		514.4±204.3b
→Gefitinibd6-10
Gefitinib d1-5		13		6.1±1.3a		7.1±1.2		126.5±20.4		1135.8±245.5
→CDDP d6-10

^aP<0.05,

^bP<0.01 vs Gefitinib (d1-5 or d1-10) group, Exp 1: first experiment, Exp 2: second experiment.